Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ze 117 St John’s wort extract to prevent relapse in moderate major depression
2005-001544-23Phase 3Completed
- Sponsor
- Max Zeller Söhne
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of St. John's wort extract Ze 117 in major depressive disorder (MDD), sponsored by Max Zeller Söhne. Primary endpoint: Avoidance of relapses. Started Apr 2007; status: completed.
02
Drugs
St. John's wort extract Ze 117
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2005-001544-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001544-23.